FREMONT, Calif.–DiscoveRx continues to innovate in field of GPCR signaling assays, tools and services and now has the largest and most comprehensive portfolio of assays and reagents for non-force coupled GPCR analysis. With a portfolio of over 300 validated assays for known and orphan GPCRs along with HitHunter™ second messenger and PathHunter™ ß-Arrestin assays and services, drug discovery researchers have expedited their GPCR drug discovery. The company expects key publications and announcements in various meetings and releases that reaffirms the value of the portfolio in GPCR drug discovery and research.

Along with ready-to-go assays, DiscoveRx also offers deorphanization, screening and profiling services for GPCR drug discovery. Now, effective January 2009, DiscoveRx is also commercializing it’s HitHunter™ cAMP kits to North American markets.

“There is no other company that offers such powerful suite of products and services that allow researchers to more thoroughly and easily interrogate GPCR signaling effects in whole cells without need of force coupling,” said Dr. Pyare Khanna, CEO of DiscoveRx.